FDC Launches Favipiravir Oral Suspension To Treat COVID-19 In India
Pharma firm FDC Ltd on Monday said it has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country. This prescription-only Favenza oral suspension is currently available at all retail medical outlets and hospital pharmacies across India, FDC said in a statement.Convenient loading dosage of the oral suspension helps reduce dosage frequency, it added."With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease.
In order to combat COVID-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of COVID-19 treatment hassle-free," FDC Business Development & Commercial Excellence General Manager Mayank Tikkha said.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!